Case Studies

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

Developing a green synthesis process for a growth promoter drug for animals

Learn how Syngene developed a green synthesis process for a growth promoter drug for an animal health company that reduced the cE factor and PMI value by 80% while achieving high yield and cost-efficiency.

Enabling a four-fold increase in titer for mAb manufacturing using Syngene's platform process

Learn how Syngene’s platform approach to mAb manufacturing helped a biopharma company achieve a four-fold increase in titer in less than a year, resulting in improved efficiency and reduced costs.

IND-enabling safety tox studies for FDA submission in just 9 months

Learn how Syngene supported a pharma company in completing IND-enabling safety tox studies for their lead compound for treating painful neuropathies in less than nine months.

Developing a unique hybridoma platform for manufacturing mAb cocktail formulations

Learn how Syngene developed a unique hybridoma platform for manufacturing mAb cocktail formulations for use in reagent kits designed to activate and expand human T cells for immunotherapy in patients.

Enhancing nanofiltration efficiency in mAb production process

Learn how Syngene enabled a major pharma company optimize the nanofiltration process to achieve efficient viral clearance while lowering operational costs.

Characterizing and predicting physical properties of hydrocarbon mixtures using AI

Learn how Syngene developed an artificial intelligence (AI) tool to reliably predict the physical properties of long-chain hydrocarbon mixtures.

Manufacturing the drug substance for Zoetis’ first-in-class mAb osteoarthritis drug

Learn how Syngene supported leading animal health company Zoetis, manufacture the drug substance for Librela® (bedinvetmab), a first-in-class monoclonal antibody, to treat osteoarthritis in dogs.

How Syngene supported a biotech company in developing a bile acid modulator for treating cholestatic diseases

Learn how Syngene successfully identified a first-in-class, potent, and efficacious inhibitor for the apical sodium-dependent bile acid transporter and sodium/taurocholate co-transporting polypeptide targets for treating cholestatic diseases.

How Syngene enabled an emerging pharma company to develop an innovative drug to treat erectile dysfunction

Learn how Syngene transitioned a drug meant for treating erectile dysfunction from late-phase discovery to early-phase clinical studies for an emerging pharma company.

Evaluating bioequivalence of an injectable for Type-2 diabetes and weight management

Learn how Syngene supported a global pharma company in conducting human pharmacological studies for Semglutide as an injectable while overcoming clinical and analytical challenges.

To view or email, Please share your details view

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details